Bioeqivalence study of new procaterol hydrochloride hydrate dry powder inhaler and the approved dry powder inhaler in patients with asthma: A randomised, double-blind phase III study

Trial Profile

Bioeqivalence study of new procaterol hydrochloride hydrate dry powder inhaler and the approved dry powder inhaler in patients with asthma: A randomised, double-blind phase III study

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Sep 2017

At a glance

  • Drugs Procaterol (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Sep 2017 New trial record
    • 01 Jan 2017 Primary endpoint of maximum FEV1 during the 480-minute measurement period has been met, according to results published in the Clinical Pharmacology in Drug Development.
    • 01 Jan 2017 Primary endpoint of area under the concentration-time curve (AUC) (FEV1)/h has been met, according to results published in the Clinical Pharmacology in Drug Development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top